Intraarticular treatment with integrin α10β1-selected mesenchymal stem cells affects microRNA expression in experimental post-traumatic osteoarthritis in horses.
Authors: Andersen Camilla, Walters Marie, Bundgaard Louise, Berg Lise Charlotte, Vonk Lucienne Angela, Lundgren-Åkerlund Evy, Henriksen Betina Lyngfeldt, Lindegaard Casper, Skovgaard Kerstin, Jacobsen Stine
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Post-traumatic osteoarthritis remains a significant welfare and economic concern in equine practice, yet the molecular mechanisms driving joint degeneration remain incompletely characterised. This 2024 study investigated how integrin α10-selected mesenchymal stem cells (MSCs) influence disease pathology by examining microRNA expression patterns in cartilage and synovial membrane harvested from horses with experimentally induced OA, comparing untreated diseased joints against both healthy controls and joints treated with allogeneic adipose-derived MSCs. The researchers quantified 70 predetermined microRNAs using quantitative PCR, successfully measuring 60 in cartilage and 55 in synovial membrane samples; three microRNAs (miR-146a, miR-150, and miR-409) were significantly upregulated in untreated OA cartilage relative to controls, whilst MSC-treated joints showed significantly reduced expression of miR-125a-3p, miR-150, miR-200c, and miR-499-5p compared to untreated OA tissue, and seven microRNAs demonstrated expression patterns correlating with histological pathology severity. The findings are particularly relevant as they identify specific molecular signatures associated with OA progression and suggest that MSC treatment—which clinically reduced tissue damage—operates partly through modulation of these regulatory molecules, offering potential biomarkers for monitoring treatment efficacy and understanding why some regenerative therapies prove more effective than others in managing joint disease.
Read the full abstract on PubMed
Practical Takeaways
- •Integrin α10-selected MSC therapy shows promise for treating post-traumatic OA by normalizing aberrant miRNA expression patterns associated with disease progression
- •miRNA profiling in cartilage and synovial membrane may help identify OA severity and predict treatment response in clinical cases
- •This foundational research supports further investigation of MSC-based therapies to reduce training loss and premature retirement due to OA-related lameness
Key Findings
- •miR-146a, miR-150, and miR-409 were significantly upregulated in untreated OA cartilage compared to healthy controls
- •MSC treatment significantly reduced expression of miR-125a-3p, miR-150, miR-200c, and miR-499-5p in OA cartilage
- •Seven miRNAs (miR-139-5p, miR-150, miR-182-5p, miR-200a, miR-378, miR-409-3p, miR-7177b) correlated with OA pathology severity scores
- •Integrin α10-selected MSCs mitigated OA severity while modulating cartilage miRNA expression patterns similar to those observed in human OA